Patents by Inventor Wenwei Huang
Wenwei Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11903929Abstract: The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.Type: GrantFiled: June 28, 2022Date of Patent: February 20, 2024Assignees: Florida State University Research Foundation, Inc., The Unites States of America, as represented by the Secretary Department of Health and Human Services, The Trustees of the University of PennsylvaniaInventors: Hengli Tang, Emily M. Lee, Wei Zheng, Ruili Huang, Miao Xu, Wenwei Huang, Khalida Shamim, Guoli Ming, Hongjun Song
-
Patent number: 11878004Abstract: The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.Type: GrantFiled: June 28, 2022Date of Patent: January 23, 2024Assignees: The United States of America, as Represented by the Secretary, Dept. of Health and Human Services, Florida Stte University Research Foundation, Inc., The Trustees of the University of PensylvaniaInventors: Hengli Tang, Emily M. Lee, Wei Zheng, Ruili Huang, Miao Xu, Wenwei Huang, Khalida Shamim, Guoli Ming, Hongjun Song
-
Publication number: 20240002332Abstract: The present disclosure relates generally to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), commonly referred to as coronavirus disease 2019 (COVID-19). The present disclosure relates more particularly to small molecule inhibitors of SARS-CoV-2 of Formula (II) and prodrug derivatives thereof of Formula (I), and methods of treating COVID-19 therewith.Type: ApplicationFiled: November 18, 2021Publication date: January 4, 2024Inventors: Wenwei Huang, Khalida Shamim, Hengli Tang
-
Patent number: 11850236Abstract: The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.Type: GrantFiled: June 28, 2022Date of Patent: December 26, 2023Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Florida State University Research Foundation, Inc., The Trustees of the University of PennsylvaniaInventors: Hengli Tang, Emily M. Lee, Wei Zheng, Ruili Huang, Miao Xu, Wenwei Huang, Khalida Shamim, Guoli Ming, Hongjun Song
-
Patent number: 11779570Abstract: The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.Type: GrantFiled: June 28, 2022Date of Patent: October 10, 2023Assignees: FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Hengli Tang, Emily M. Lee, Wei Zheng, Ruili Huang, Miao Xu, Wenwei Huang, Khalida Shamim, Guoli Ming, Hongjun Song
-
Publication number: 20230301984Abstract: Method embodiments are disclosed for treating retinal degeneration in a subject in need thereof. In some embodiments, the method comprises administering to the subject a therapeutically effective amount of compound, and/or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, or tautomer thereof, selected from 3-(dibutylamino)-1-(1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl)propan-1-ol hydrochloride or a compound having a structure according to a formula selected from Formula I, II, or III, as described herein. In some non-limiting examples, the subject has retinitis pigmentosa, LCA, Stargardt’s macular dystrophy, cone-rod dystrophy, choroideremia or age-related macular degeneration.Type: ApplicationFiled: July 1, 2021Publication date: September 28, 2023Applicant: The USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Anand Swaroop, Yu Holly Chen, Manju Swaroop, Wei Zheng, Gregory Tawa, Anupam Mondal, Samantha Papal, Wenwei Huang, Zhiji Luo
-
Patent number: 11753408Abstract: Disclosed are compounds of formula (I) and formula (II): wherein R1, R2, A, and B are as defined herein. Also disclosed is a method of blocking transmission of a Plasmodium parasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula (I) or (II) either alone or in combination with a second compound selected from elesclomol, NSC174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat.Type: GrantFiled: April 22, 2021Date of Patent: September 12, 2023Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Loyola University of ChicagoInventors: Wenwei Huang, Hao Li, Wei Sun, Xiuli Huang, Paresma R. Patel, Hangmao Sun, Wei Zheng, Xiao Lu, Philip E. Sanderson, Myunghoon Kim, Meghan J. Orr, Gregory J. Tawa, Kim C. Williamson
-
Patent number: 11654147Abstract: The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to treat subjects with Sjögren's syndrome, or diffuse intrinsic pontine glioma (DIPG).Type: GrantFiled: June 7, 2021Date of Patent: May 23, 2023Assignees: The Brigham and Women's Hospital, Inc., The United States of America, as Represented by the Secretary, Dept. of Health and Human ServicesInventors: Paul B. Yu, Wenwei Huang, Philip Edward Sanderson, Jian-Kang Jiang, Khalida Shamim, Wei Zheng, Xiuli Huang, Gregory Tawa, Arthur Lee, Asaf Alimardanov, Junfeng Huang
-
Publication number: 20230000869Abstract: The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to treat subjects with Sjögren's syndrome, or diffuse intrinsic pontine glioma (DIPG).Type: ApplicationFiled: June 7, 2021Publication date: January 5, 2023Inventors: Paul B. Yu, Wenwei Huang, Philip Edward Sanderson, Jian-Kang Jiang, Khalida Shamim, Wei Zheng, Xiuli Huang, Gregory Tawa, Arthur Lee, Asaf Alimardanov, Junfeng Huang
-
Publication number: 20220362217Abstract: The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.Type: ApplicationFiled: June 28, 2022Publication date: November 17, 2022Inventors: HENGLI TANG, EMILY M. LEE, WEI ZHENG, RUILI HUANG, MIAO XU, WENWEI HUANG, KHALIDA SHAMIM, GUOLI MING, HONGJUN SONG
-
Publication number: 20220331293Abstract: The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.Type: ApplicationFiled: June 28, 2022Publication date: October 20, 2022Inventors: Hengli TANG, Emily M. LEE, Wei ZHENG, Ruili HUANG, Miao XU, Wenwei HUANG, Khalida SHAMIM, Guoli MING, Hongjun SONG
-
Patent number: 11471443Abstract: The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.Type: GrantFiled: April 29, 2020Date of Patent: October 18, 2022Assignees: FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC., The United States of America, as represented by the Secretary, Department of Health and Human Service, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Hengli Tang, Emily M. Lee, Wei Zheng, Ruili Huang, Miao Xu, Wenwei Huang, Khalida Shamim, Guoli Ming, Hongjun Song
-
Publication number: 20220323419Abstract: The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.Type: ApplicationFiled: June 28, 2022Publication date: October 13, 2022Inventors: HENGLI TANG, EMILY M. LEE, WEI ZHENG, RUILI HUANG, MIAO XU, WENWEI HUANG, KHALIDA SHAMIM, GUOLI MING, HONGJUN SONG
-
Publication number: 20220323420Abstract: The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.Type: ApplicationFiled: June 28, 2022Publication date: October 13, 2022Inventors: HENGLI TANG, EMILY M. LEE, WEI ZHENG, RUILI HUANG, MIAO XU, WENWEI HUANG, KHALIDA SHAMIM, GUOLI MING, HONGJUN SONG
-
Patent number: 11207315Abstract: The present invention concerns the use of emetine compounds for the treatment or prevention of Flavivirus infections, such as dengue virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus infection, by administering an emetine compound such as emetine or cephaeline, or a combination of two or more emetine compounds, to a subject in need thereof; methods for inhibiting Flavivirus infections such as dengue virus infections in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Flavivirus infections, such dengue virus infections.Type: GrantFiled: December 18, 2019Date of Patent: December 28, 2021Assignees: Florida State University Research Foundation, Inc., The Johns Hopkins University, The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Hengli Tang, Emily M. Lee, Anil Mathew Tharappel, Hongjun Song, Guo-Li Ming, Wei Zheng, Miao Xu, Shu Yang, Ruili Huang, Wenwei Huang, Khalida Shamim, Hao Li
-
Patent number: 11096927Abstract: The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.Type: GrantFiled: December 19, 2019Date of Patent: August 24, 2021Assignees: FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Hengli Tang, Emily M. Lee, Wei Zheng, Ruili Huang, Miao Xu, Wenwei Huang, Khalida Shamim, Guoli Ming, Hongjun Song
-
Publication number: 20210246137Abstract: Disclosed are compounds of formula (I) and formula (II): wherein R1, R2, A, and B are as defined herein. Also disclosed is a method of blocking transmission of a Plasmodium parasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula (I) or (II) either alone or in combination with a second compound selected from elesclomol, NSC174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat.Type: ApplicationFiled: April 22, 2021Publication date: August 12, 2021Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, Loyola University of ChicagoInventors: Wenwei Huang, Hao Li, Wei Sun, Xiuli Huang, Paresma R. Patel, Hangmao Sun, Wei Zheng, Xiao Lu, Philip E. Sanderson, Myunghoon Kim, Meghan J. Orr, Gregory J. Tawa, Kim C. Williamson
-
Publication number: 20210188843Abstract: Disclosed are compounds of formula (I) wherein R1, R2, R3, A, and B are as defined herein, and a method of preparing such compounds. Also disclosed are pharmaceutical compositions containing the compound of formula (I) and a method of blocking transmission of a Plasmodium parasite and a method of treating or preventing malaria by killing or arresting the growth of Plasmodium organisms in a mammal, wherein the Plasmodium organisms are in a liver stage, an asexual stage, or gametocytes, comprising administering to an animal an effective amount of a compound of formula (I).Type: ApplicationFiled: May 13, 2019Publication date: June 24, 2021Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, The Henry M. Jackson Foundation for the Advancment of Military Medicine, Inc.Inventors: Wenwei Huang, Hao Li, Wei Zheng, Wei Sun, Xiuli Huang, Xiao Lu, Philip E. Sanderson, Xin Xu, Pranav Shah, Kim C. Williamson, Zhiji Luo, Gregory J. Tawa
-
Patent number: 11026947Abstract: The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to treat subjects with Sjögren's syndrome, or diffuse intrinsic pontine glioma (DIPG).Type: GrantFiled: April 26, 2018Date of Patent: June 8, 2021Assignees: The Brigham and Women's Hospital, Inc., The United States of America, as Represented by the Secretary, Dept, of Health and Human ServicesInventors: Paul B. Yu, Wenwei Huang, Philip Edward Sanderson, Jian-Kang Jiang, Khalida Shamim, Wei Zheng, Xiuli Huang, Gregory Tawa, Arthur Lee, Asaf Alimardanov, Junfeng Huang
-
Patent number: 10988472Abstract: Disclosed are compounds of formula (I) and formula (II): (I) (II) wherein R1, R2, A, and B are as defined herein. Also disclosed is a method of blocking transmission of a Plasmodium parasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula (I) or (II) either alone or in combination with a second compound selected from elesclomol, NSC174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat.Type: GrantFiled: October 13, 2017Date of Patent: April 27, 2021Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Loyola University of ChicagoInventors: Wenwei Huang, Hao Li, Wei Sun, Xiuli Huang, Paresma R. Patel, Hangmao Sun, Wei Zheng, Xiao Lu, Philip E. Sanderson, Myunghoon Kim, Meghan J. Orr, Gregory J. Tawa, Kim C. Williamson